Health Economics›Gallbladder cancer›Metastatic disease second-line

Metastatic disease second-line

Gallbladder cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FULV and nanoliposomal Irinotecan Variant #01 Partial	—	R 1 617	14d	~7.1 mo	~7.1 mo	~16	~R 25 874 PFS proxy · indirect	4
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.5 mo	~2	~R 95 PFS proxy · indirect	16
CAPIRI N/A - secondary systemic drug	—	R 1	21d	~5.9 mo	~16.8 mo	~9	~R 12 PFS proxy · indirect	2

4 of 4 regimens shown